Toronto, Ontario, Canada, September 16, 2026
Thryv Therapeutics has announced the publication of new research in JACC: Heart Failure providing converging human genetic, preclinical, and clinical evidence supporting the continued development of THRV-1268, the company’s investigational selective SGK1 inhibitor for heart failure. The publication brings together evidence from multiple research approaches to evaluate the role of serum and glucocorticoid-regulated kinase 1 (SGK1) in cardiovascular disease and provides scientific support for advancing THRV-1268 into a Phase 2a clinical development program. The company is investigating whether inhibition of SGK1 can influence biological pathways involved in heart failure and potentially address disease mechanisms that remain insufficiently treated by existing therapies.
Human Genetic Evidence Supports SGK1 Target
Heart failure is a complex cardiovascular condition in which the heart cannot adequately pump blood to meet the body’s needs. Although modern treatments have improved outcomes for many patients, significant morbidity and mortality remain, creating continued demand for new therapeutic targets and treatment approaches. The research published in JACC: Heart Failure examines evidence linking SGK1 activity with cardiovascular disease biology. Human genetic analyses provide one component of the evidence package, allowing researchers to investigate associations between genetic variation affecting SGK1-related pathways and cardiovascular outcomes. Human genetic evidence can be valuable during drug discovery because it may help determine whether modulation of a biological target is associated with disease risk or clinical outcomes in human populations. Thryv Therapeutics said the combined evidence strengthens the scientific rationale for targeting SGK1 in heart failure. The company is using this target-validation approach to support development of THRV-1268, a selective small-molecule inhibitor designed to inhibit SGK1 activity.
Preclinical and Clinical Evidence Converge
In addition to human genetic findings, the publication incorporates preclinical research examining the biological consequences of SGK1 inhibition. Preclinical studies are important for determining whether modulation of a target produces relevant effects in experimental models before larger clinical studies are conducted.According to the company, the overall evidence package includes findings from human genetics, experimental models, and clinical research, creating a broader assessment of the potential therapeutic relevance of SGK1 inhibition. The convergence of different evidence streams is intended to provide greater confidence in the biological rationale for THRV-1268 as the program moves through clinical development. The publication also includes early clinical evidence generated during development of THRV-1268. Early-stage clinical studies primarily provide information regarding safety, tolerability, pharmacokinetics, and pharmacodynamic effects, while subsequent trials are needed to establish whether a candidate produces meaningful clinical benefits for patients.Thryv Therapeutics is using the available evidence to support progression into a Phase 2a study, where the company expects to investigate THRV-1268 in patients with heart failure and gather additional information about its therapeutic potential.
Advertisement
THRV-1268 Moves Toward Phase 2a Development
The planned Phase 2a development program represents the next stage in evaluating THRV-1268. Unlike early Phase 1 studies, which primarily focus on safety and drug behavior, Phase 2 studies generally provide an opportunity to investigate biological activity and preliminary evidence of efficacy in patients with the target disease. For THRV-1268, the Phase 2a program is intended to further evaluate the potential of SGK1 inhibition in heart failure while continuing to characterize the candidate’s safety and pharmacological effects. Data generated during this stage could help determine appropriate dosing strategies, identify relevant patient populations, and guide subsequent clinical development.
The publication is particularly relevant to the broader field of cardiovascular drug discovery, where researchers are increasingly combining human genetic evidence with experimental biology and clinical data to validate therapeutic targets. Such integrated approaches can help pharmaceutical developers prioritize targets with evidence connecting molecular mechanisms to human disease. Thryv Therapeutics’ latest publication therefore represents a development milestone for the THRV-1268 heart failure program. By bringing together human genetic, preclinical, and clinical evidence, the research provides a comprehensive scientific foundation for continued investigation of SGK1 inhibition. The planned Phase 2a program will provide an important opportunity to determine whether the biological rationale observed across these evidence streams translates into meaningful effects in patients with heart failure. Further clinical studies will ultimately be required to establish the safety and efficacy of THRV-1268 and determine its potential role in cardiovascular treatment.
Source: Thryv Therapeutics press release
